Cimetidine Hydrochloride

Zollinger-Ellison Syndrome, Indigestion, Heartburn + 11 more

Treatment

12 FDA approvals

20 Active Studies for Cimetidine Hydrochloride

What is Cimetidine Hydrochloride

Cimetidine

The Generic name of this drug

Treatment Summary

Cimetidine is a drug used to block the activity of histamine, which is a chemical released in the body when an allergic reaction occurs. It works by blocking the activity of histamine on special receptors in the body and can be used to reduce acid production in the stomach, reduce pepsin and gastrin production, and block the activity of cytochrome P-450. Cimetidine is sometimes used in cancer treatments.

Cimetidine

is the brand name

image of different drug pills on a surface

Cimetidine Hydrochloride Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cimetidine

Cimetidine

1994

91

Approved as Treatment by the FDA

Cimetidine, also known as Cimetidine, is approved by the FDA for 12 uses which include Adenoma and Heartburn .

Adenoma

Helps manage multiple endocrine adenomas

Heartburn

Helps manage Gastro-esophageal Reflux Disease (GERD)

multiple endocrine adenomas

Helps manage multiple endocrine adenomas

benign gastric ulcers

Gastro-esophageal Reflux Disease (GERD)

Helps manage Gastro-esophageal Reflux Disease (GERD)

Zollinger-Ellison Syndrome

Helps manage Zollinger-Ellison Syndrome

Gastric hypersecretion

Helps manage Gastric hypersecretion

active Duodenal ulcer

Systemic Mastocytosis

Helps manage Systemic Mastocytosis

Gastric ulcer

Duodenal Ulcer

Mastocytosis, Systemic

Helps manage Systemic Mastocytosis

Effectiveness

How Cimetidine Hydrochloride Affects Patients

Cimetidine helps reduce stomach acid and is used to treat gastric and duodenal ulcers, heartburn, and other conditions that involve too much acid secretion. It does this by blocking the histamine H2 receptors in the stomach. Cimetidine also affects certain enzymes in the liver and increases the amount of certain types of bacteria in the stomach.

How Cimetidine Hydrochloride works in the body

Cimetidine works by blocking histamine receptors on the stomach. This stops the body from producing too much stomach acid and reduces the amount of acid in the stomach.

When to interrupt dosage

The recommended measure of Cimetidine Hydrochloride is contingent upon the diagnosed condition, including Acid indigestion, Cystic Fibrosis (CF) and Systemic Mastocytosis. Dosage fluctuates in accordance with the mode of delivery (e.g. Liquid or Intramuscular; Intravenous) delineated in the following table.

Condition

Dosage

Administration

Heartburn

, 300.0 mg, 400.0 mg, 800.0 mg, 200.0 mg, 300.0 mg/mL, 600.0 mg, 100.0 mg, 6.0 mg/mL, 150.0 mg/mL, 0.1 mg/mg, 0.05 mg/mg, 400.0 mg/mL, 60.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Liquid, Liquid - Oral, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intravenous, Intravenous, Solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Cream, Topical, Cream - Topical, Gel, Gel - Topical

Gastric hypersecretion

, 300.0 mg, 400.0 mg, 800.0 mg, 200.0 mg, 300.0 mg/mL, 600.0 mg, 100.0 mg, 6.0 mg/mL, 150.0 mg/mL, 0.1 mg/mg, 0.05 mg/mg, 400.0 mg/mL, 60.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Liquid, Liquid - Oral, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intravenous, Intravenous, Solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Cream, Topical, Cream - Topical, Gel, Gel - Topical

Zollinger-Ellison Syndrome

, 300.0 mg, 400.0 mg, 800.0 mg, 200.0 mg, 300.0 mg/mL, 600.0 mg, 100.0 mg, 6.0 mg/mL, 150.0 mg/mL, 0.1 mg/mg, 0.05 mg/mg, 400.0 mg/mL, 60.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Liquid, Liquid - Oral, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intravenous, Intravenous, Solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Cream, Topical, Cream - Topical, Gel, Gel - Topical

Indigestion

, 300.0 mg, 400.0 mg, 800.0 mg, 200.0 mg, 300.0 mg/mL, 600.0 mg, 100.0 mg, 6.0 mg/mL, 150.0 mg/mL, 0.1 mg/mg, 0.05 mg/mg, 400.0 mg/mL, 60.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Liquid, Liquid - Oral, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intravenous, Intravenous, Solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Cream, Topical, Cream - Topical, Gel, Gel - Topical

Heartburn

, 300.0 mg, 400.0 mg, 800.0 mg, 200.0 mg, 300.0 mg/mL, 600.0 mg, 100.0 mg, 6.0 mg/mL, 150.0 mg/mL, 0.1 mg/mg, 0.05 mg/mg, 400.0 mg/mL, 60.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Liquid, Liquid - Oral, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intravenous, Intravenous, Solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Cream, Topical, Cream - Topical, Gel, Gel - Topical

Duodenal Ulcer

, 300.0 mg, 400.0 mg, 800.0 mg, 200.0 mg, 300.0 mg/mL, 600.0 mg, 100.0 mg, 6.0 mg/mL, 150.0 mg/mL, 0.1 mg/mg, 0.05 mg/mg, 400.0 mg/mL, 60.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Liquid, Liquid - Oral, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intravenous, Intravenous, Solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Cream, Topical, Cream - Topical, Gel, Gel - Topical

NSAID use

, 300.0 mg, 400.0 mg, 800.0 mg, 200.0 mg, 300.0 mg/mL, 600.0 mg, 100.0 mg, 6.0 mg/mL, 150.0 mg/mL, 0.1 mg/mg, 0.05 mg/mg, 400.0 mg/mL, 60.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Liquid, Liquid - Oral, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intravenous, Intravenous, Solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Cream, Topical, Cream - Topical, Gel, Gel - Topical

Adenoma

, 300.0 mg, 400.0 mg, 800.0 mg, 200.0 mg, 300.0 mg/mL, 600.0 mg, 100.0 mg, 6.0 mg/mL, 150.0 mg/mL, 0.1 mg/mg, 0.05 mg/mg, 400.0 mg/mL, 60.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Liquid, Liquid - Oral, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intravenous, Intravenous, Solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Cream, Topical, Cream - Topical, Gel, Gel - Topical

Cystic Fibrosis

, 300.0 mg, 400.0 mg, 800.0 mg, 200.0 mg, 300.0 mg/mL, 600.0 mg, 100.0 mg, 6.0 mg/mL, 150.0 mg/mL, 0.1 mg/mg, 0.05 mg/mg, 400.0 mg/mL, 60.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Liquid, Liquid - Oral, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intravenous, Intravenous, Solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Cream, Topical, Cream - Topical, Gel, Gel - Topical

Gastric ulcer

, 300.0 mg, 400.0 mg, 800.0 mg, 200.0 mg, 300.0 mg/mL, 600.0 mg, 100.0 mg, 6.0 mg/mL, 150.0 mg/mL, 0.1 mg/mg, 0.05 mg/mg, 400.0 mg/mL, 60.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Liquid, Liquid - Oral, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intravenous, Intravenous, Solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Cream, Topical, Cream - Topical, Gel, Gel - Topical

Mastocytosis, Systemic

, 300.0 mg, 400.0 mg, 800.0 mg, 200.0 mg, 300.0 mg/mL, 600.0 mg, 100.0 mg, 6.0 mg/mL, 150.0 mg/mL, 0.1 mg/mg, 0.05 mg/mg, 400.0 mg/mL, 60.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Liquid, Liquid - Oral, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intravenous, Intravenous, Solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Cream, Topical, Cream - Topical, Gel, Gel - Topical

Gastrointestinal Symptoms

, 300.0 mg, 400.0 mg, 800.0 mg, 200.0 mg, 300.0 mg/mL, 600.0 mg, 100.0 mg, 6.0 mg/mL, 150.0 mg/mL, 0.1 mg/mg, 0.05 mg/mg, 400.0 mg/mL, 60.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Liquid, Liquid - Oral, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intravenous, Intravenous, Solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Cream, Topical, Cream - Topical, Gel, Gel - Topical

Duodenum

, 300.0 mg, 400.0 mg, 800.0 mg, 200.0 mg, 300.0 mg/mL, 600.0 mg, 100.0 mg, 6.0 mg/mL, 150.0 mg/mL, 0.1 mg/mg, 0.05 mg/mg, 400.0 mg/mL, 60.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Liquid, Liquid - Oral, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intravenous, Intravenous, Solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Cream, Topical, Cream - Topical, Gel, Gel - Topical

Stomach Ulcer

, 300.0 mg, 400.0 mg, 800.0 mg, 200.0 mg, 300.0 mg/mL, 600.0 mg, 100.0 mg, 6.0 mg/mL, 150.0 mg/mL, 0.1 mg/mg, 0.05 mg/mg, 400.0 mg/mL, 60.0 mg/mL

Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Liquid, Liquid - Oral, Liquid - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intravenous, Intravenous, Solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Cream, Topical, Cream - Topical, Gel, Gel - Topical

Warnings

Cimetidine Hydrochloride Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Cimetidine may interact with Pulse Frequency

There are 20 known major drug interactions with Cimetidine Hydrochloride.

Common Cimetidine Hydrochloride Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Cimetidine.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Cimetidine.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Cimetidine.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Cimetidine.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Cimetidine.

Cimetidine Hydrochloride Toxicity & Overdose Risk

If someone takes too much cimetidine, it is important to keep their airway and heart rate stable. The patient should be carefully monitored and given any necessary medical care. If needed, treatments like stomach pumping and activated charcoal may be used.

image of a doctor in a lab doing drug, clinical research

Cimetidine Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Cimetidine Hydrochloride?

27 active clinical trials are currently assessing the potential of Cimetidine Hydrochloride to relieve Heartburn, Duodenal and Duodenal Ulcer symptoms.

Condition

Clinical Trials

Trial Phases

NSAID use

0 Actively Recruiting

Stomach Ulcer

0 Actively Recruiting

Zollinger-Ellison Syndrome

0 Actively Recruiting

Heartburn

2 Actively Recruiting

Phase 3, Not Applicable

Indigestion

6 Actively Recruiting

Phase 3, Not Applicable, Phase 2

Gastric ulcer

0 Actively Recruiting

Duodenum

0 Actively Recruiting

Duodenal Ulcer

0 Actively Recruiting

Cystic Fibrosis

0 Actively Recruiting

Mastocytosis, Systemic

0 Actively Recruiting

Gastrointestinal Symptoms

2 Actively Recruiting

Not Applicable

Adenoma

0 Actively Recruiting

Heartburn

12 Actively Recruiting

Phase 3, Phase 2, Not Applicable

Gastric hypersecretion

0 Actively Recruiting

Patient Q&A Section about cimetidine hydrochloride

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Why was cimetidine taken off the market?

"The FDA has warned that some common heartburn medications may contain NDMA, a substance classified as a probable human carcinogen by the World Health Organization."

Answered by AI

What is the major side effect of cimetidine?

"Headaches, dizziness, drowsiness and diarrhea may occur. If any of these effects persist or worsen, notify your doctor immediately."

Answered by AI

What is cimetidine hydrochloride used for?

"This medicine is an antihistamine that blocks the release of stomach acid. It is used to treat stomach or intestinal ulcers. It can relieve ulcer pain and discomfort, and the heartburn from acid reflux."

Answered by AI

Clinical Trials for Cimetidine Hydrochloride

Image of University of California, Irvine - UCI Medical Center in Orange, United States.

Sling-Fiber Preservation vs. Conventional POEM for Achalasia

18+
All Sexes
Orange, CA

Peroral endoscopic myotomy (POEM) is an effective, minimally invasive treatment for achalasia, offering excellent rates of symptom relief. However, a significant drawback is the high incidence of gastroesophageal reflux disease (GERD) following the procedure. One proposed technical modification, the selective preservation of the sling fibers during gastric myotomy (SFP-POEM), may reduce this risk without compromising efficacy as compared to a conventional POEM procedure, which includes myotomy of the sling fibers. In this study, adults with achalasia will be randomly assigned to receive one of the two POEM technical approaches. Researchers will monitor whether preserving sling fibers reduces the rates of reflux esophagitis (classified as Los Angeles Grade B or higher) on follow-up endoscopy. Participants will be followed for up to 1 year after the procedure.

Waitlist Available
Has No Placebo

University of California, Irvine - UCI Medical Center

Jason Samarasena, MD, MBA

Image of Del Sol Research Management, LLC in Tucson, United States.

Linaprazan Glurate vs Lansoprazole for Acid Reflux

18 - 80
All Sexes
Tucson, AZ

The goal of this clinical trial is to find out how well linaprazan glurate can heal erosive esophagitis (EE) caused by gastroesophageal reflux disease (GERD), compared to lansoprazole, a commonly used medication. Researchers will also evaluate whether linaprazan glurate: * Reduces heartburn symptoms more effectively than lansoprazole * Is safe and well tolerated, based on physical exams, blood tests, and vital signs (heart rate, blood pressure, temperature, and breathing rate) * Causes any side effects during treatment * Has different effects depending on how much of the drug is in the blood * Works differently depending on participants' genes Participants must be between 18 to 80 years old and have EE due to GERD confirmed by an endoscopy. Participants cannot join if they have an active Helicobacter pylori (HP) infection or were treated for HP in the past 6 weeks or have taken antibiotics or bismuth-containing drugs in the past 6 weeks. The study is a randomized, double-blind, active comparator-controlled trial lasting up to 4 months. Randomized means that participants are assigned by chance (like flipping a coin) to one of the treatment groups and double-blind means neither the participants nor the study team will know which treatment is given. Participants will be placed into one of three groups (about 167 people in each group): * Linaprazan glurate 50 mg twice a day * Linaprazan glurate 50 mg once a day * Lansoprazole 30 mg once a day Everyone will take 2 tablets and 1 capsule by mouth daily for 8 weeks. Some tablets or capsules will be placebos (look like medicine but contain no active drug). Participants will: * Undergo an endoscopy in the beginning and after 4 weeks of treatment * If healing is not observed, another endoscopy may be done at 8 weeks * During the procedure, doctors will use a thin, flexible tube with a camera to look at the esophagus and take small tissue samples (biopsies) * Have blood and urine tests at clinic visits to check overall health * Receive electrocardiograms (ECGs) to monitor heart function * Complete daily questionnaires on an electronic device about symptoms and experiences

Phase 3
Waitlist Available

Del Sol Research Management, LLC (+24 Sites)

Cinclus Pharma Holding AB

Image of Mayo Clinic in Rochester in Rochester, United States.

High Resolution Gastric Mapping and Gastroduodenal Manometry for Indigestion

18 - 80
All Sexes
Rochester, MN

Dyspepsia is a common problem attributed to gastric sensorimotor dysfunctions ie, delayed, or less frequently rapid gastric emptying (GE), impaired gastric accommodation, and increased gastric sensation. Therapeutic options manage symptoms, and there is no FDA approved medical therapy for dyspepsia. There is a need for better objective understanding of sensorimotor dysfunction in dyspepsia, as well as noninvasive, efficacious, safe, and inexpensive treatments for dyspepsia. The purpose of this research is to identify disturbances and characterize phenotypes in patients with functional dyspepsia, and to assess the correlations between symptoms (during the manometry and in daily life), gastric emptying, electrical activity (BSGM), and pressure activity (manometry).

Recruiting
Has No Placebo

Mayo Clinic in Rochester

Nicholas R Oblizajek, MD

Have you considered Cimetidine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Cimetidine Hydrochloride, we think they might fit your search criteria.
Go to Trials
Image of G. Oppenheimer Center for Neurobiology of Stress and Resilience in Los Angeles, United States.

Biofeedback for Functional Abdominal Bloating

18 - 80
All Sexes
Los Angeles, CA

Background. Abdominal distention is produced by an abnormal somatic postural tone. The authors developed an original biofeedback technique. In a randomized, placebo-controlled trial the authors demonstrated the superiority of biofeedback over placebo for the treatment of abdominal distention. However, the technique is technically complex and unpractical. Aim. To prove the efficacy of a noninstrumental biofeedback technique, transmitted by a standard training program, for the treatment of abdominal distension in different centers. Selection criteria. Episodes of visible abdominal distension. Intervention. Patients will be randomized into biofeedback and placebo groups. Three sessions of either biofeedback or placebo intervention will be performed during the first 3 weeks of the intervention period. Biofeedback: Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. In each center one operator will receive a standard training on how to deliver the noninstrumental biofeedback treatment. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period. Placebo: Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.

Recruiting
Paid Trial

G. Oppenheimer Center for Neurobiology of Stress and Resilience (+1 Sites)

Fernando Azpiroz, MD

Image of Cleveland Clinic Center for Abdominal Core Health in Cleveland, United States.

Mesh vs Pledgets for Hernia Repair

18+
All Sexes
Cleveland, OH

The goal of this clinical trial is to compare whether the use of Ovitex mesh provides superior reduction in 2-year recurrence compared to pledgeted suture closure (no mesh) for patients undergoing paraesophageal hernia repair at the Cleveland Clinic. The main questions it aims to answer are: * Determine whether there is a difference in 2-year rates of radiographic recurrence with Ovitex versus pledgeted sutures in paraesophageal hernia repair. * Assess patient quality of life (QOL) after paraesophageal hernia repair with pledgets and mesh. A two-tailed research hypothesis will be used to determine whether there are differences between the two arms

Recruiting
Has No Placebo

Cleveland Clinic Center for Abdominal Core Health

David M Krpata, MD

Image of Memphis VA Medical Center, Memphis, TN in Memphis, United States.

Oral Glutamine for Gulf War Syndrome

18 - 65
All Sexes
Memphis, TN

Many veterans with Gulf War Illness developed chronic gastrointestinal symptoms during their deployment to the Persian Gulf. The pathophysiologic mechanisms of these chronic gastrointestinal symptoms are not well understood but cause significant morbidity in veterans. Our proposed studies will provide an innovative and novel treatment trial for chronic gastrointestinal symptoms in veterans with Gulf War Illness that were deployed into war zones. Given that there are currently no specific treatments for these disorders, and that current symptomatic approaches are far from ideal, proof of principle of our trial would be an extremely important advance as it would not only have a beneficial impact on the health of many thousands of our veterans, but also it would substantially reduce the many negative economic effects of this ailment on the VA Health Care System.

Recruiting
Dietary Supplement

Memphis VA Medical Center, Memphis, TN

QiQi Zhou, MD PhD

Have you considered Cimetidine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Cimetidine Hydrochloride, we think they might fit your search criteria.
Go to Trials

Have you considered Cimetidine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Cimetidine Hydrochloride, we think they might fit your search criteria.
Go to Trials